Degrees Pharmaceuticals has received approval from the IRB for a Phase II trial of Arakoda (tafenoquine) for treating chronic babesiosis.

The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...

ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients with Grade 1 or 2 gastroenteropancreatic ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

Akero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated ...

Fortress Biotech, Helocyte have announced the dosing of the first subject in the trial of Triplex for individuals who are ...

Arena International’s Outsourcing in Clinical Trials West Coast 2025 will discuss patient centricity, diversity, and ...

California medical device company RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP) system has shown potential for improved ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

The Phase I ADC trial will evaluate the safety and efficacy of the company’s drug which targets tumours whilst leaving normal ...

Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...